Newron Pharmaceuticals SpA (NWRN) — Capital Reinvestment Ratio

Latest as of June 2025: 0.00x

Newron Pharmaceuticals SpA (NWRN) has a Capital Reinvestment Ratio of 0.00x as of June 2025, meaning it reinvests 0% of its operating cash flow (CHF33.35 Million) in capital expenditures (CHF31.00K). See Newron Pharmaceuticals SpA balance sheet independence to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

CHF33.35 Million
CHF

Capital Expenditures

CHF31.00K
CHF

Data as of

Jun 2025
Most recent filing

Newron Pharmaceuticals SpA Capital Reinvestment Ratio (2012–2025)

This chart tracks Newron Pharmaceuticals SpA's Capital Reinvestment Ratio across 2 annual periods. Check NWRN total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Newron Pharmaceuticals SpA (2012–2025)

Year-by-year Capital Reinvestment Ratio for Newron Pharmaceuticals SpA from 2012 to 2025. For live market cap and broader valuation context, see Newron Pharmaceuticals SpA stock valuation.

Year Reinvestment Ratio Operating CF (CHF) Capital Expenditures YoY Change
2025 0.00x CHF32.56 Million CHF47.30K ▼ -23.1%
2012 0.00x CHF5.83 Million CHF11.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow